This research targets chronic lymphocytic leukemia relapse by focusing on Bruton’s Tyrosine Kinase (BTK), a key cancer-driving protein that often mutates and becomes drug-resistant. Using “molecular glues,” the project aims to degrade BTK—even when mutated—offering a new therapeutic strategy that could overcome resistance and improve outcomes for (chronic lymphocytic leukemia) CLL and other BTK-dependent cancers.

This research investigates a novel two-drug therapy for ovarian cancer that kills cancer cells without harming healthy tissues and partially reactivates the suppressed immune system. The PhD work explores how this immune “reawakening” occurs, aiming to identify new strategies to enhance it and create more effective, resistance-proof treatments.

This research investigates how Plasmodium falciparum invades human red blood cells. By focusing on the neglected role of red cell surface structures, it aims to uncover molecular interactions essential for invasion. Understanding these mechanisms may guide the development of new treatments for drug-resistant malaria, a disease killing a child every minute.